Aleniglipron delivers 12%; Trump splits the MMR
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Structure Therapeutics' aleniglipron — once-daily oral GLP-1 pill produced 12.1% body weight loss over 36 weeks in a 230-patient phase II, versus 0.5% on placebo, per Nature Medicine.link ›
- Dr. Robert Kushner at Northwestern co-authored the study across 38 U.S. medical centers, testing 45mg, 90mg, and 120mg doses with or without food.link ›
- Aleniglipron is chemically synthesized rather than peptide-based — a structure Kushner said enables easier large-scale manufacturing and combination with other medications.link ›
- University of Vienna researchers used whole-brain MRI on 12 trained pet dogs and, per iScience, delivered the first brain-level evidence that dogs distinguish fearful faces from angry or sad ones.link ›
- Dr. Laura Cuaya co-led a separate canine MRI experiment showing dog brains differentiate happy from neutral human faces via visual, social, and reward processing regions.link ›
- Synchron, Motif Neurotech, Precision Neuroscience, and Merge Labs all market brain-computer interfaces as "minimally invasive" — Anna Wexler calls the term fuzzy with no standardized clinical meaning.link ›
- Trump's vaccine executive order splits MMR into three separate doses, a claim he admitted has no evidentiary basis and which his own health officials publicly contradicted.link ›
- Harvard's Bala Subramaniam argues pop concerts are public health infrastructure, citing neuroimaging on default mode network suppression and research showing synchronized dancing with out-group members boosts real-life cooperation.link ›
Structure Therapeutics dropped a phase II dataset that should make Eli Lilly and Novo Nordisk nervous. Aleniglipron, a once-daily oral GLP-1 pill, took 12.1% of body weight off patients over 36 weeks in a 230-patient trial — performance competitive with injectable Wegovy and Ozempic, but delivered in a tablet that doesn't need refrigeration, isn't peptide-based, and can be manufactured at industrial scale. If phase III holds, this is the supply-chain unblocker the obesity drug market has been waiting for. In Washington, Trump's executive order splitting MMR into three separate doses — with no supporting evidence and his own health officials publicly contradicting him — turned federal immunization policy into a presidential preference.
The stories behind this week
Dogs' Brains Distinguish Human Fear From Anger or SadnessThis research shifts understanding of canine cognition by showing dogs process nuanced human emotions neurologically, not just behaviorally. The finding that dogs distinguish fear from other negative expressions suggests they may assess threat type differently, which could improve training methods and human-dog communication strategies.
Aleniglipron Pill Delivers 12% Weight Loss in TrialIf phase III succeeds, aleniglipron could become the first once-daily oral GLP-1 therapy competitive with Wegovy and Ozempic, bypassing the injection, refrigeration, and peptide-manufacturing bottlenecks that have limited supply. For the roughly 230-patient efficacy set already shown, the 9–12% weight reduction lands close to what injectable semaglutide delivers in a similar window.
2026 Total Solar Eclipse: Path from Russia to SpainIceland's next total solar eclipse after August 2026 won't come until 2196 — a 170-year gap — making this the only chance in several lifetimes for anyone alive today to see totality from Reykjavík, while viewers across a quarter of the planet catch a partial eclipse requiring certified eye protection throughout.
Neurotech startups use 'minimally invasive' with no clear definitionPatients may misunderstand the risks of experimental brain implants if 'minimally invasive' is taken at face value, while companies gain a PR advantage by using an undefined term that sounds safer—this asymmetry could shape informed consent and public trust in emerging neurotech.
Solar Eclipse Unites Public in Awe, Highlights Scientific LegacyScientific understanding of eclipses has repeatedly shifted from myth to tool—from Anaxagoras’ breakthrough to British-led validation of Einstein’s relativity—showing how natural phenomena can alter power dynamics and deepen human knowledge when observed systematically. The 1919 expeditions, funded and logistically backed by imperial institutions, produced results that transcended national enmities just months after WWI, proving science’s capacity to unify even amid geopolitical fracture.
Trump Orders Vaccine Changes Without EvidenceThe move puts Trump at odds with medical consensus and key health stakeholders, risking erosion of public trust in vaccination programs. With no data backing the new schedule, implementation could delay immunizations and increase preventable disease outbreaks, undermining long-standing public health efforts.
Neuroscientist: Pop Concerts Are Public Health InfrastructureSubramaniam — who directs the Sadhguru Center for a Conscious Planet at Harvard — is leveraging a Durkheimian framework and his own neuroimaging research to argue that the decline of communal dance spaces is a measurable public health problem, not a cultural preference, and that treating the dancefloor as infrastructure could be as consequential as anti-smoking campaigns once were for loneliness-related disease.
Scotland sees partial solar eclipse through cloudy skiesThe eclipse offered a rare astronomical opportunity for public engagement in Scotland, but inconsistent visibility limited widespread observation. The event’s timing—just before sunset and amid unpredictable weather—meant only those in elevated, west-facing locations with momentary cloud breaks fully benefited, highlighting the challenge of planning for transient celestial events in temperate climates.
Why it matters: If phase III holds, aleniglipron becomes the first oral GLP-1 that can compete with injectable semaglutide — collapsing the cold-chain and peptide-manufacturing moat that has defined the obesity drug market since Wegovy launched.
Ask SkimNews
